NEXTBio Capital Management LP — 13F Holdings & Portfolio
CIK 2038158 · latest 13F-HR filed 2026-05-14
NEXTBio Capital Management LP manages $215.4M in 13F-reported U.S. long-equity assets across 24 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are TERN (14.80%), PTGX (11.24%), STTK (9.40%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 1 new position, exited 0, added to 17, and trimmed 4.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$215.4M
Long-equity book
24
Distinct positions
2026-03-31
Filed 2026-05-14
+1 / −0 / ↑17 / ↓4
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- TERNS PHARMACEUTICALS INC$9.6M +43.1%
- SHATTUCK LABS INC$8.8M +76.2%
- COMPASS PATHWAYS PLC$6.0M +115.3%
- VOR BIOPHARMA INC$4.8M +36.4%
- PROTAGONIST THERAPEUTICS INC$4.1M +20.7%
Top Trims
- ZENAS BIOPHARMA INC-$3.3M -28.6%
- VERASTEM INC-$3.2M -31.4%
- COMPASS THERAPEUTICS INC-$1.5M -25.0%
- ADICET BIO INC-$254.1K -19.1%
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | TERNS PHARMACEUTICALS INC | TERN | 880881107 | $31.9M | 14.80% | 604,534 | SH |
| 2 | PROTAGONIST THERAPEUTICS INC | PTGX | 74366E102 | $24.2M | 11.24% | 229,619 | SH |
| 3 | SHATTUCK LABS INC | STTK | 82024L103 | $20.3M | 9.40% | 3,149,907 | SH |
| 4 | VOR BIOPHARMA INC | VOR | 929033207 | $17.8M | 8.28% | 999,967 | SH |
| 5 | COMPASS PATHWAYS PLC | CMPS | 20451W101 | $11.2M | 5.19% | 2,021,407 | SH |
| 6 | RHYTHM PHARMACEUTICALS INC | RYTM | 76243J105 | $11.0M | 5.09% | 126,078 | SH |
| 7 | XENON PHARMACEUTICALS INC | XENE | 98420N105 | $10.7M | 4.95% | 183,225 | SH |
| 8 | PALVELLA THERAPEUTICS INC NE | PVLA | 697947109 | $10.3M | 4.79% | 82,686 | SH |
| 9 | ZENAS BIOPHARMA INC | ZBIO | 98937L105 | $8.3M | 3.87% | 426,736 | SH |
| 10 | INVENTIVA SA | IVA | 46124U107 | $7.4M | 3.44% | 1,333,484 | SH |
| 11 | VERASTEM INC | VSTM | 92337C203 | $6.9M | 3.22% | 1,306,800 | SH |
| 12 | CRESCENT BIOPHARMA INC. | CBIO | G2545C104 | $6.8M | 3.18% | 372,856 | SH |
| 13 | ORIC PHARMACEUTICALS INC | ORIC | 68622P109 | $6.6M | 3.08% | 523,619 | SH |
| 14 | STRUCTURE THERAPEUTICS INC | GPCR | 86366E106 | $6.4M | 2.98% | 133,239 | SH |
| 15 | VAXCYTE INC | PCVX | 92243G108 | $5.5M | 2.57% | 95,223 | SH |
| 16 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $5.0M | 2.34% | 131,188 | SH |
| 17 | COMPASS THERAPEUTICS INC | CMPX | 20454B104 | $4.5M | 2.08% | 848,204 | SH |
| 18 | EVOMMUNE INC | EVMN | 30054Y107 | $4.2M | 1.96% | 184,063 | SH |
| 19 | OCULIS HOLDING AG | OCS | H5870P102 | $4.0M | 1.85% | 149,592 | SH |
| 20 | ZAI LAB LTD | ZLAB | 98887Q104 | $3.4M | 1.60% | 183,362 | SH |
| 21 | DISC MEDICINE INC | IRON | 254604101 | $3.4M | 1.56% | 52,655 | SH |
| 22 | KALVISTA PHARMACEUTICALS INC | KALV | 483497103 | $2.7M | 1.23% | 131,796 | SH |
| 23 | SUMMIT THERAPEUTICS INC | SMMT | 86627T108 | $1.7M | 0.79% | 89,717 | SH |
| 24 | ADICET BIO INC | ACET | 007002207 | $1.1M | 0.50% | 157,827 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-14 | $215.4M | 24 | 0001172661-26-001957 |
| 2025-12-31 | 2026-02-13 | $170.5M | 23 | 0001172661-26-000761 |